Clinical trials: in Romania
Pancreatic Adenocarcinoma
The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma still represents one of the "hot-topics" worldwide. Endoscopic ultrasonography was a breakthrough, bringing us closer to personalized treatment by getting histopathological samples through…
- Trial name
- EUS-FNA (NCT04765410)
- Testing
- EUS FNA (endoscopic ultrasound fine needle aspiration)
- Where
- 5 sites in Romania
- Volunteers
- 57 people
- Sponsor
- Carol Davila University of Medicine and Pharmacy
Primary Sjogrens Disease
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD).
- Trial name
- Unity (NCT06684847)
- Testing
- Efgartigimod PH20 SC
- Where
- 303 sites in United States, Argentina and 37 more
- Volunteers
- 631 people
- Sponsor
- argenx
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe…
- Trial name
- TITANIA (NCT05158387)
- Testing
- Tozorakimab
- Where
- 212 sites in United States, Australia and 18 more
- Volunteers
- 1,172 people
- Sponsor
- AstraZeneca
Asthma
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function…
- Trial name
- ATLAS (NCT05097287)
- Testing
- Dupilumab
- Where
- 249 sites in United States, Belgium and 21 more
- Volunteers
- 1,339 people
- Sponsor
- Sanofi
CML, Relapsed, CML, Refractory
Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments
The main study (CLR_15_03) was terminated prematurely for non-safety reasons due to changes in the clinical treatment landscape and evolving regulatory considerations.
- Trial name
- NCT07517315
- Testing
- K0706
- Where
- 10 sites in United States, France and 5 more
- Sponsor
- Sun Pharma Advanced Research Company Limited
HIV-1-infection
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
The goal of this clinical study is to learn more about the experimental drugs lepetegravir (formerly GS-1720) (an oral, long-acting integrase strand transfer inhibitor (INSTI)) and lenacapavir pacfosacil (formerly GS-4182) (a…
- Trial name
- WONDERS2 (NCT06613685)
- Testing
- lepetegravir, lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide
- Where
- 58 sites in United States, Canada and 7 more
- Volunteers
- 73 people
- Sponsor
- Gilead Sciences
Multiple Myeloma
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
- Trial name
- NCT02719613
- Testing
- Elotuzumab, Dexamethasone, Lenalidomide
- Where
- 41 sites in United States, Australia and 11 more
- Volunteers
- 67 people
- Sponsor
- Bristol-Myers Squibb
Crohn's Disease (CD)
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab.
- Trial name
- SEQUENCE (NCT04524611)
- Testing
- Risankizumab, Ustekinumab
- Where
- 300 sites in United States, Argentina and 29 more
- Volunteers
- 527 people
- Sponsor
- AbbVie
Venous Thromboembolism
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'.
- Trial name
- ROXI-CATH (NCT06299111)
- Testing
- REGN9933, REGN7508
- Where
- 23 sites in United States, Bulgaria and 4 more
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Hepatitis b
Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
This three-part, Phase 1 protocol will be the first clinical study of AB-101. Parts 1 and 2 will be a Phase 1a SAD/MAD of AB-101 in healthy adult subjects.
- Trial name
- NCT05960240
- Testing
- AB-101, Nucleos(t)ide Analogue
- Where
- 10 sites in Hong Kong, Italy and 5 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Colitis, Ulcerative
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.
- Trial name
- ANTHEM-UC (NCT06049017)
- Testing
- JNJ-77242113
- Where
- 177 sites in United States, Argentina and 19 more
- Volunteers
- 252 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
The goal of this study is to learn if emvistegrast (formerly GS-1427) is effective in treating participants with moderate to severe ulcerative colitis.
- Trial name
- SWIFT (NCT06290934)
- Testing
- emvistegrast
- Where
- 181 sites in United States, Australia and 20 more
- Volunteers
- 228 people
- Sponsor
- Gilead Sciences
Crohn's Disease
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.
- Trial name
- U-ENDURE (NCT03345823)
- Testing
- Upadacitinib
- Where
- 466 sites in United States, Argentina and 47 more
- Volunteers
- 747 people
- Sponsor
- AbbVie
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer.
- Trial name
- FIERCE-HN (NCT06064877)
- Testing
- Ficlatuzumab, Cetuximab
- Where
- 112 sites in United States, Australia and 16 more
- Volunteers
- 410 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Metastatic NSCLC
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to investigate the efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in participants with untreated metastatic non-squamous NSCLC (irrespective of PD-L1 status)…
- Trial name
- NCT06159790
- Testing
- GME751, Keytruda-EU
- Where
- 62 sites in United States, Bosnia and Herzegovina and 14 more
- Volunteers
- 218 people
- Sponsor
- Sandoz
Diffuse Large B-Cell Lymphoma
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- EPCORE DLBCL-4 (NCT06508658)
- Testing
- Epcoritamab, Rituximab, Lenalidomide
- Where
- 176 sites in United States, Argentina and 26 more
- Volunteers
- 379 people
- Sponsor
- Genmab
Schizophrenia
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013).
- Trial name
- NCT05211947
- Testing
- Iclepertin
- Where
- 303 sites in United States, Argentina and 38 more
- Volunteers
- 1,356 people
- Sponsor
- Boehringer Ingelheim
Viral Hepatitis
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
- Trial name
- NCT06903338
- Testing
- Tobevibart, Elebsiran
- Where
- 39 sites in United States, Canada and 8 more
- Volunteers
- 124 people
- Sponsor
- Vir Biotechnology, Inc.
Renal Impairment, End-stage Kidney Disease
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants
A study to investigate the pharmacokinetics, safety, and tolerability of AZD4144 in participants with severe renal impairment, end-stage kidney disease, and in healthy participants.
- Conditions
- Renal Impairment, End-stage Kidney Disease, Healthy Participants
- Trial name
- NCT06693765
- Testing
- AZD4144
- Where
- 2 sites in Bulgaria, Romania
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Left Ventricular Dyssynchrony, Heart Failure
AMEND-CRT: Mechanical Dyssynchrony as Selection Criterion for CRT
Previous experience with cardiac resynchronization therapy (CRT) candidates suggests that selection of these patients can be improved.
- Conditions
- Left Ventricular Dyssynchrony, Heart Failure, Cardiomyopathy, Dilated, Cardiac Remodeling, Ventricular
- Trial name
- AMEND-CRT (NCT04225520)
- Testing
- Cardiac resynchronization therapy ON, Cardiac resynchronization therapy OFF
- Where
- 24 sites in Belgium, Brazil and 9 more
- Volunteers
- 500 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.